Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRN OTCMKTS:BVNRY NASDAQ:EXAS NYSE:QGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$54.09-3.3%$58.02$52.93▼$85.00$10.74B0.351.66 million shs1.93 million shsBVNRYBavarian Nordic$12.18-0.5%$11.52$6.60▼$12.50$2.90B1.33,102 shs3,208 shsEXASExact Sciences$53.94-3.7%$48.86$38.81▼$72.83$10.60B1.052.84 million shs2.32 million shsQGENQiagen$45.30-1.7%$48.47$37.63▼$51.88$10.24B0.641.32 million shs992,179 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical0.00%-6.37%-6.74%-3.79%-36.20%BVNRYBavarian Nordic0.00%-1.05%-1.58%+29.44%+5.02%EXASExact Sciences0.00%+0.24%+19.89%+0.78%-15.88%QGENQiagen0.00%-4.70%-7.46%-3.77%+1.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$54.09-3.3%$58.02$52.93▼$85.00$10.74B0.351.66 million shs1.93 million shsBVNRYBavarian Nordic$12.18-0.5%$11.52$6.60▼$12.50$2.90B1.33,102 shs3,208 shsEXASExact Sciences$53.94-3.7%$48.86$38.81▼$72.83$10.60B1.052.84 million shs2.32 million shsQGENQiagen$45.30-1.7%$48.47$37.63▼$51.88$10.24B0.641.32 million shs992,179 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical0.00%-6.37%-6.74%-3.79%-36.20%BVNRYBavarian Nordic0.00%-1.05%-1.58%+29.44%+5.02%EXASExact Sciences0.00%+0.24%+19.89%+0.78%-15.88%QGENQiagen0.00%-4.70%-7.46%-3.77%+1.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRNBioMarin Pharmaceutical 2.69Moderate Buy$92.0470.16% UpsideBVNRYBavarian Nordic 0.00N/AN/AN/AEXASExact Sciences 2.88Moderate Buy$68.0526.16% UpsideQGENQiagen 2.27Hold$49.699.68% UpsideCurrent Analyst Ratings BreakdownLatest BVNRY, BMRN, EXAS, and QGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025EXASExact SciencesCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $85.009/8/2025BMRNBioMarin PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$60.009/4/2025EXASExact SciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/3/2025BMRNBioMarin PharmaceuticalRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$85.008/13/2025BMRNBioMarin PharmaceuticalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/12/2025EXASExact SciencesBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $60.008/11/2025EXASExact SciencesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$70.00 ➝ $60.008/8/2025EXASExact SciencesEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$68.00 ➝ $64.008/7/2025QGENQiagenCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/7/2025EXASExact SciencesCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/7/2025EXASExact SciencesUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$61.00 ➝ $53.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRNBioMarin Pharmaceutical$3.06B3.39$3.14 per share17.22$29.69 per share1.82BVNRYBavarian Nordic$829.12M3.48$1.01 per share12.09$6.99 per share1.74EXASExact Sciences$2.76B3.70$5.43 per share9.94$12.98 per share4.16QGENQiagen$2.04B4.94$3.15 per share14.37$16.05 per share2.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRNBioMarin Pharmaceutical$426.86M$3.3716.0512.410.7121.45%12.59%10.13%11/4/2025 (Estimated)BVNRYBavarian Nordic$143.26M$0.8714.0011.60N/A21.95%12.35%10.11%11/14/2025 (Estimated)EXASExact Sciences-$1.03B-$5.43N/A107.885.73-34.19%-1.75%-0.76%11/4/2025 (Estimated)QGENQiagen$83.59M$1.6926.7618.412.4318.30%14.77%8.87%11/5/2025 (Estimated)Latest BVNRY, BMRN, EXAS, and QGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/22/2025Q2 2025BVNRYBavarian NordicN/A$0.23N/A$0.23N/A$251.14 million8/6/2025Q2 2025EXASExact Sciences-$0.02$0.22+$0.24-$0.01$774.43 million$811.09 million8/5/2025Q2 2025QGENQiagen$0.60$0.60N/A$0.44$523.97 million$533.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/ABVNRYBavarian NordicN/AN/AN/AN/AN/AEXASExact SciencesN/AN/AN/AN/AN/AQGENQiagen$0.250.55%N/A14.79%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRNBioMarin Pharmaceutical0.105.563.60BVNRYBavarian NordicN/A3.351.74EXASExact Sciences0.942.892.56QGENQiagen0.251.611.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRNBioMarin Pharmaceutical98.71%BVNRYBavarian NordicN/AEXASExact Sciences88.82%QGENQiagen70.00%Insider OwnershipCompanyInsider OwnershipBMRNBioMarin Pharmaceutical0.85%BVNRYBavarian NordicN/AEXASExact Sciences1.20%QGENQiagen9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRNBioMarin Pharmaceutical3,040192.02 million190.38 millionOptionableBVNRYBavarian Nordic1,611236.57 millionN/ANot OptionableEXASExact Sciences7,000189.32 million187.05 millionOptionableQGENQiagen5,765222.29 million202.29 millionOptionableBVNRY, BMRN, EXAS, and QGEN HeadlinesRecent News About These CompaniesRhumbline Advisers Sells 11,088 Shares of Qiagen N.V. $QGENSeptember 14 at 5:26 AM | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $5.42 Million Holdings in Qiagen N.V. $QGENSeptember 14 at 3:35 AM | marketbeat.comAQR Capital Management LLC Purchases 73,122 Shares of QIAGEN N.V. $QGENSeptember 14 at 3:24 AM | marketbeat.comBarclays’ Significant Stake in QIAGEN Revealed by AFMSeptember 12 at 8:47 PM | msn.comQiagen N.V. (QGEN) Launches QIAseq xHYB Panels for Long-Read SequencingSeptember 11 at 2:32 PM | msn.comFinancial Comparison: QIAGEN (NYSE:QGEN) and Polyrizon (NASDAQ:PLRZ)September 11 at 2:11 AM | americanbankingnews.com7 Hot Healthcare Stocks To Buy Right NowSeptember 10, 2025 | insidermonkey.comQiagen N.V. (QGEN) Presents At Baird Global Healthcare Conference 2025 Prepared Remarks TranscriptSeptember 10, 2025 | seekingalpha.comQIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx PortfolioSeptember 10, 2025 | businesswire.comQiagen N.V. Announces Voting Rights NotificationSeptember 9, 2025 | msn.comQiagen N.V. (QGEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comCubist Systematic Strategies LLC Trims Stock Position in Qiagen N.V. $QGENSeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Buys 82,372 Shares of Qiagen N.V. $QGENSeptember 8, 2025 | marketbeat.comVident Advisory LLC Makes New $604,000 Investment in QIAGEN N.V. $QGENSeptember 8, 2025 | marketbeat.comNitorum Capital L.P. Makes New Investment in Qiagen N.V. $QGENSeptember 7, 2025 | marketbeat.comQiagen N.V. $QGEN Shares Sold by AmundiSeptember 7, 2025 | marketbeat.comEdmond DE Rothschild Holding S.A. Trims Position in Qiagen N.V. $QGENSeptember 6, 2025 | marketbeat.comQiagen N.V. Announces Voting Rights Notification by AFMSeptember 6, 2025 | msn.comPDT Partners LLC Trims Stake in Qiagen N.V. $QGENSeptember 5, 2025 | marketbeat.comPerbak Capital Partners LLP Lowers Position in QIAGEN N.V. $QGENSeptember 4, 2025 | marketbeat.comQiagen launches US FDA approved higher-throughput QIAstat-Dx Rise, a version of the QIAstat-Dx automated syndromic testing systemSeptember 3, 2025 | pharmabiz.comPNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025It May Be Time to Buy the Dip in Texas InstrumentsBy Chris Markoch | September 12, 2025BVNRY, BMRN, EXAS, and QGEN Company DescriptionsBioMarin Pharmaceutical NASDAQ:BMRN$54.09 -1.82 (-3.26%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$54.50 +0.41 (+0.76%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Bavarian Nordic OTCMKTS:BVNRY$12.18 -0.06 (-0.49%) As of 09/12/2025 03:04 PM EasternBavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.Exact Sciences NASDAQ:EXAS$53.94 -2.06 (-3.68%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$52.14 -1.80 (-3.34%) As of 09/12/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Qiagen NYSE:QGEN$45.30 -0.76 (-1.65%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$45.29 -0.01 (-0.02%) As of 09/12/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
